Drugs / Satraplatin

Trials 17 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT01259479 Dec 2010 → Aug 2013 metastatic malignant neoplasm in the brain National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT01220284 Feb 2008 → Nov 2010 cancer Southern Europe New Drug Organization Unknown No outcome recorded
Phase 1 NCT00480623 May 2007 → Mar 2008 prostate cancer Agennix Terminated No outcome recorded
Phase 1 NCT00473720 May 2007 → Jun 2010 high grade malignant neoplasm Yale University Completed No outcome recorded
Phase 1 NCT00125411 Mar 2007 → Feb 2009 neoplasm Agennix Terminated No outcome recorded
Phase 1 NCT00329329 May 2006 → Jan 2009 cancer Agennix Terminated No outcome recorded
Phase 1 NCT00313456 Mar 2006 → Mar 2009 prostate cancer Agennix Terminated No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00093132 Aug 2004 → Jan 2009 non-small cell lung carcinoma Agennix Terminated No outcome recorded
Phase 25 trials
Phase 2 NCT01289067 Dec 2010 → May 2013 prostate cancer William K. Oh Completed No outcome recorded
Phase 2 NCT00634647 Feb 2008 → Feb 2011 prostate cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00370383 Jul 2006 → Feb 2009 lung cancer Agennix Completed No outcome recorded
Phase 2 NCT00268970 Dec 2005 → Apr 2007 non-small cell lung carcinoma Agennix Completed No outcome recorded
Phase 2 NCT00265655 Nov 2005 → Jan 2008 breast cancer Agennix Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03258320 Jan 2015 → Dec 2026 expected prostate cancer Shanghai Jiao Tong University School of Medicine Recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT00450970 Feb 2007 → Mar 2009 prostate cancer Agennix Terminated No outcome recorded
Phase 3 NCT00069745 Sep 2003 → Jan 2006 hormone-resistant prostate carcinoma Agennix Completed No outcome recorded
Phase not applicable1 trial
NCT00499694 Oct 2007 → Nov 2012 prostate cancer Barbara Ann Karmanos Cancer Institute Completed No outcome recorded

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

FieldValueCited text
Known as Satraplatin ClinicalTrials.gov intervention name — accepted as the source's own label NCT00265655
16

NCT00329329

NCT00370383

NCT00125411

NCT00634647

NCT01259479

NCT00093132

NCT00480623

NCT01289067

NCT00499694

NCT00313456

NCT00450970

NCT01220284

NCT00069745

NCT00268970

NCT00473720

NCT03258320

Known as - Satraplatin (codenamed JM216) - Satraplatin (codenamed JM216)NCT01220284
Known as bis-aceto-ammine dischlorocyclohexylamine platinum “Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue” NCT00370383
Known as BMS-182751 ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367
Known as BMY-45594 ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367
Known as JM-216 “Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of...” NCT00450970
2

“Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue” NCT00370383

“investigational, oral cytotoxic drug, satraplatin (JM-216), in combination with docetaxel” NCT00125411

Known as NSC-744226 ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367
Known as OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV) “Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of...” NCT00450970
Known as Satraplatine ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367
Known as Satraplatino ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367
Modality Other / unclassified “member of the platinum-based class of chemotherapy drugs” NCT00125411
Route Oral “satraplatin can be given orally” NCT00069745